Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: A retrospective case series of 31 patients

Pharmacotherapy

Volumn 26, Issue 3, 2006, Pages 347-352

  Segreti, John A ^a   Crank, Christopher W ^a   Finney, Michael S ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Fountain Valley Regional Hospital and Medical Center   (United States)

Author keywords

Bacteremia; Bloodstream infections; Daptomycin; Drug resistance; Infective endocarditis

Indexed keywords

AMIKACIN; CEFEPIME; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; OXACILLIN; RIFAMPICIN; TOBRAMYCIN; VANCOMYCIN;

ADULT; AGED; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIUM CULTURE; CLINICAL ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAM POSITIVE BACTERIUM; HOSPITAL DISCHARGE; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; RETROSPECTIVE STUDY; REVIEW; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS; FEMALE; HUMANS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN RESISTANCE;

EID: 33644694712     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.3.347     Document Type: Review

References (13)

1. Laupland KB, Gregson DB, Zygun DA, Doig CJ, Mortis G, Church DL. Severe bloodstream infections: a population-based assessment. Crit Care Med 2004;32:992-7.
2. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239-44.
3. NNIS System. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992-June 2004, issued October 2004. Am J Infect Control 2004;32:470-85.
4. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-9.
5. Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29:1171-7.
6. Fowler VGJ, Kong LK, Corey GR, et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999;179:1157-61.
7. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402.
8. Thorne GM. Daptomycin: a novel lipopeptide antibiotic. Clin Microbiol Newsl 2002;24:33-40.
9. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI, for the Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2004;38:1673-81.
10. Laganas V, Alder J, Silverman JA. In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis. Antimicrob Agents Chemother 2003;47:2682-4.
11. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;30:633-8.
12. Cubist Pharmaceuticals. Cubicin (daptomycin for injection) product information. Lexington, MA; 2003.
13. Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000;44:2948-53.